Medication info
Dapagloem Extended-Release Tablet 10/500 mg

Dapagloem Extended-Release Tablet 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hallym Pharmaceutical Co., Ltd.
Appearance
A pink, oval, dual-convex, extended-release film-coated tablet
Packaging
PTP - 30 tablets/box [(6 tablets/PTP) × 5]
Approval status
Active

MFDS item code 202300240 · Approved 2023.01.12 · Insurance code 645306850

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medication should provide the same dose of metformin the patient was taking, or the nearest therapeutically appropriate dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and below 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be evaluated every 3~6 months. Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).

Ingredients

Manufacturer
Hallym Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood glucose control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used primarily as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Especially, the combined administration of dapagliflozin and metformin effectively manages blood glucose levels. It is also important to refer to expert guidance regarding the effects of the medication on the occurrence of cardiovascular events for patients with cardiovascular disease or risk factors among those whose blood glucose is not adequately controlled. In summary, this drug helps in blood glucose control and cardiovascular health management in adults with type 2 diabetes.

How to take

Adult dose

The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medication should provide the same dose of metformin the patient was taking, or the nearest therapeutically appropriate dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and below 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be evaluated every 3~6 months. Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).

Precautions

This medication aids in glucose control. However, it is necessary to be cautious as it may rarely lead to a serious condition called lactic acidosis. Care should be taken when taken alongside insulin or sulfonylurea medications as it may exacerbate hypoglycemia. It should not be used in patients with severely impaired renal function, dehydration, severe infections, or cardiovascular issues. Additionally, it should not be used in pregnant or breastfeeding women, nor in patients with genetic issues such as lactose intolerance. Patients with reduced fluid volume or impaired renal function should use this medication with caution and check periodically for symptoms of hypotension or changes in renal function. This medication may increase the risk of genital infections or urinary tract infections, so immediate treatment is necessary if symptoms appear. Moreover, this drug can decrease vitamin B12 levels, so it is advisable to check vitamin B12 concentrations during prolonged use. Excessive alcohol consumption should be avoided during treatment, and the medication should be temporarily discontinued prior to surgery or radiographic contrast examinations. Dose adjustments may be required when used alongside medications that pose a risk of hypoglycemia. This medication has not been sufficiently evaluated for safety and efficacy in children or elderly patients, hence caution is required. In case of overdose, seek appropriate medical care immediately, and store this medication out of reach of children.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • pulmonary malignant neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbances
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • asthenia
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent moisture and air ingress. It is important to maintain the storage temperature between 1 and 30 degrees Celsius at room temperature. This will help maintain the medication's effectiveness.

Appearance and packaging

Appearance

A pink, oval, dual-convex, extended-release film-coated tablet

Package unit

PTP - 30 tablets/box [(6 tablets/PTP) × 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.